Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDZBQH)

Drug Name

FTY720-phosphate Drug Info

Synonyms

fingolimod phosphate

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 9908268
ChEBI ID: CHEBI:73420
CAS Number: CAS 402616-23-3
TTD Drug ID: DMDZBQH

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Patented Agent(s)

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Sphingosine-1-phosphate receptor 3 (S1PR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9522888, 575	DM6UXZK	N. A.	N. A.	Patented	[6]
US9617250, Example 1 Example 204 of D1	DM89LKQ	N. A.	N. A.	Patented	[7]
YYDJCLCSBYCSCO-UHFFFAOYSA-N	DMA91FM	N. A.	N. A.	Patented	[8]
US9216972, 61	DM7AHQE	N. A.	N. A.	Patented	[9]
US9670220, 77	DMZG1HO	N. A.	N. A.	Patented	[10]
US10179791, Compound 296	DMLZBRM	N. A.	N. A.	Patented	[11]
JCXGHZCWAHCYGY-UHFFFAOYSA-N	DMER7QX	N. A.	N. A.	Patented	[8]
US9216972, 67	DMXR5SZ	N. A.	N. A.	Patented	[9]
US10166249, Example 695	DMVMNP1	N. A.	N. A.	Patented	[12]
US9181182, 40	DM3QIF4	N. A.	N. A.	Patented	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Sphingosine-1-phosphate receptor 1 (S1PR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siponimod	DM2R86O	Multiple sclerosis	8A40	Approved	[14]
Fingolimod	DM5JVAN	Multiple sclerosis	8A40	Approved	[15]
Ozanimod	DMT6AM2	Multiple sclerosis	8A40	Approved	[16]
Etrasimod	DMT0A3Y	Ulcerative colitis	DD71	Approved	[17]
Ponesimod	DMEAOYJ	Multiple sclerosis	8A40	Approved	[18]
MT-1303	DMSE9TH	Crohn disease	DD70	Phase 2	[19]
ONO-4641	DMLUM3Y	Rheumatoid arthritis	FA20	Phase 2	[20]
KRP-203	DMOW9X2	Cutaneous lupus erythematosus	EB5Z	Phase 2	[20]
VTX-002	DMZ8Z5A	Ulcerative colitis	DD71	Phase 2	[21]
CBP-307	DM3TH6Y	Ulcerative colitis	DD71	Phase 2	[22]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Sphingosine-1-phosphate receptor 4 (S1PR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AUY954	DMVGIO5	Discovery agent	N.A.	Investigative	[23]
AFD(R)	DME9Y8Q	Discovery agent	N.A.	Investigative	[24]
VPC03090-P	DMIXUM3	Discovery agent	N.A.	Investigative	[25]
dihydrosphingosine-1-phosphate	DM58KHY	N. A.	N. A.	Investigative	[26]
KRP 203-phosphate	DMLIK7X	Discovery agent	N.A.	Investigative	[27]
phytosphingosine 1-phosphate	DMWJCST	Discovery agent	N.A.	Investigative	[26]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Targeting Sphingosine-1-phosphate receptor 5 (S1PR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASP-4058	DM1RD0T	Multiple sclerosis	8A40	Phase 1	[28]
AUY954	DMVGIO5	Discovery agent	N.A.	Investigative	[23]
AFD(R)	DME9Y8Q	Discovery agent	N.A.	Investigative	[24]
VPC03090-P	DMIXUM3	Discovery agent	N.A.	Investigative	[25]
VPC44116	DMQ4OTJ	Discovery agent	N.A.	Investigative	[29]
------------------------------------------------------------------------------------

Drug(s) Affected By Sphingosine 1-phosphate receptor 1 (S1PR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[30]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[31]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[32]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[33]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[34]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[35]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[36]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[37]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[38]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[39]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[40]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[41]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[42]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[43]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[44]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[45]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[46]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[47]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[48]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[49]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[50]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[41]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[51]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[52]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[53]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[40]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[54]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[55]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[43]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[44]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sphingosine-1-phosphate receptor 1 (S1PR1)	TT9JZCK	S1PR1_HUMAN	Agonist	[2]
Sphingosine-1-phosphate receptor 3 (S1PR3)	TTDYP7I	S1PR3_HUMAN	Agonist	[3]
Sphingosine-1-phosphate receptor 4 (S1PR4)	TTZ8C5Q	S1PR4_HUMAN	Agonist	[2]
Sphingosine-1-phosphate receptor 5 (S1PR5)	TTDZCKV	S1PR5_HUMAN	Agonist	[3]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Post-Translational Modifications	[4]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Post-Translational Modifications	[4]
Sphingosine 1-phosphate receptor 1 (S1PR1)	OTLTXDQT	S1PR1_HUMAN	Drug Response	[5]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2924).
2	The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453-7.
3	Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004 May;309(2):758-68.
4	Adverse effect of FTY720P on colonic Na(+) /K(+) ATPase is mediated via ERK, p38MAPK, PKC, and PI3K. J Appl Toxicol. 2023 Feb;43(2):220-229. doi: 10.1002/jat.4375. Epub 2022 Aug 17.
5	Structural insights into sphingosine-1-phosphate receptor activation. Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2117716119. doi: 10.1073/pnas.2117716119. Epub 2022 Apr 11.
6	Substituted bicyclic compounds. US9522888.
7	Pyridin-4-yl derivatives. US9617250.
8	6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519.
9	Tricyclic heterocyclic compounds. US9216972.
10	Fused heterocyclic derivatives as S1P modulators. US9670220.
11	Spiro-cyclic amine derivatives as S1P modulators. US10179791.
12	Substituted bicyclic compounds. US10166249.
13	S1P receptors modulators. US9181182.
14	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
15	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
16	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
17	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
19	Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
20	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
21	Clinical pipeline report, company report or official report of Ventyx Biosciences
22	Clinical pipeline report, company report or official report of Connect Biopharma
23	A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34.
24	Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839-48.
25	Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89.
26	Phytosphingosine 1-phosphate: a high affinity ligand for the S1P(4)/Edg-6 receptor. Biochem Biophys Res Commun. 2002 Sep 27;297(3):600-6.
27	A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-d... J Pharmacol Exp Ther. 2008 Jan;324(1):276-83.
28	ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.
29	Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77.
30	Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb Haemost. 2008 Jul;100(1):119-26.
31	THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
32	The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
33	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
34	Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
35	Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
36	Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol. 2011 Feb 18;24(2):165-7. doi: 10.1021/tx1004419. Epub 2011 Feb 4.
37	Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
38	Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
39	Ceramide in the molecular mechanisms of neuronal cell death. The role of sphingosine-1-phosphate. Mol Neurobiol. 2014 Aug;50(1):26-37. doi: 10.1007/s12035-013-8606-4. Epub 2014 Jan 14.
40	Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
41	Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
42	Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
43	Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
44	Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
45	Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
46	Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
47	Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
48	Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
49	SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
50	Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
51	A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
52	The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
53	Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
54	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
55	Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.